HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Abstract Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (18) Citing Articles via Google Scholar Google Scholar Articles by Kalra, S. Articles by Rihal, C. S. Search for Related Content PubMed PubMed Citation Articles by Kalra, S. Articles by Rihal, C. S.

Alveolar Hemorrhage as a Complication of Treatment With Abciximab^*

^* From the Division of Pulmonary and Critical Care Medicine (Dr. Kalra), and Division of Cardiovascular Diseases (Drs. Bell and Rihal), Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN.

Correspondence to: Sanjay Kalra, MD, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: kalra.sanjay{at}mayo.edu

	Abstract

TOP Abstract Introduction Materials and Methods Results Discussion References

 
Study objective: The use of abciximab, a chimeric monoclonal antibody Fab fragment specific for platelet glycoprotein IIb/IIIa receptors, is associated with improved outcome after angioplasty and stent placement. Major complications include bleeding, but pulmonary hemorrhage has been reported rarely. This study was done to identify patients with pulmonary hemorrhage following abciximab infusion and to define, if possible, any specific risk factors.

Design: Retrospective review of institutional coronary angiography and bronchoscopy databases to identify patients who received abciximab and developed pulmonary hemorrhage.

Setting: Tertiary-care teaching hospital.

Patients: All patients who underwent coronary angiography and received abciximab between June 1995 and March 2000.

Intervention: None.

Measurements and results: Seven of 2,553 patients (0.27%) had documented severe pulmonary hemorrhage associated with chest radiographic abnormalities, impaired oxygenation, and the need for blood product transfusions. The initial symptom was hemoptysis in four of the seven patients. There were two early deaths and one late death. No cases of pulmonary hemorrhage were identified in 5,412 patients who underwent coronary procedures without abciximab infusion. No other risk factors predicting hemorrhage were identified.

Conclusions: Severe pulmonary hemorrhage is a complication of abciximab use. Although hemoptysis is an important alerting symptom, it may not be present initially and the diagnosis may be missed or considered late, with the potential for inappropriate treatment until the diagnosis is established. Lesser degrees of bleeding are potentially easily missed, and this report should alert physicians to this complication so that it can be considered early in the evaluation of patients presenting with pulmonary events after abciximab use.

Key Words: abciximab • alveolar hemorrhage • complications • ReoPro

	Introduction

TOP Abstract Introduction Materials and Methods Results Discussion References

 
The infusion of abciximab (ReoPro; Eli Lilly; Indianapolis, IN), a chimeric monoclonal antibody Fab fragment specific for platelet glycoprotein IIb/IIIa receptors, has been shown to improve the short-term outcome of patients who undergo coronary angioplasty and stent placement.^{1 2 3 4} Abciximab, in conjunction with heparin and other antiplatelet therapy such as aspirin, ticlopidine, or clopidogrel, is usually administered as a bolus 10 to 60 min before the procedure, followed by continuous infusion for 12 h. Major and minor bleeding complications are well recognized^{2 4} but can be reduced by less intense anticoagulation with heparin and early arterial access sheath removal.^{5 6} The majority of bleeding complications occur in the absence of thrombocytopenia,⁶ another well-documented adverse effect in 1 to 5% of patients.⁷ Thrombocytopenia varies from mild to profound and usually occurs within 24 h after initial exposure to the drug.⁷ Most bleeding events represent arterial access complications and as such are easily recognized, as are both GI and genitourinary hemorrhaging, which occur less frequently. Intracranial bleeding has been documented but is rare.^{1 2 3 4}

Anecdotal instances of pulmonary hemorrhage, thought to be related to abciximab, in our practice prompted this study. Such bleeding is less easily diagnosed than hemorrhage in other sites and is possibly frequently misidentified. Bleeding into the lung parenchyma may present as new radiologic infiltrates or respiratory symptoms other than hemoptysis. Reports of the frequency and severity of alveolar hemorrhage after abciximab use are sparse,^{8 9} and it is quite likely that bleeding events are misdiagnosed, most frequently as pneumonia.

We undertook a review of the records of all patients who received abciximab during coronary intervention procedures at our institution between June 1995 and March 2000. The aim was to identify patients with either an established or possible diagnosis of alveolar hemorrhage to allow us to assess the frequency of this complication as well as to elucidate, if possible, any useful information that might enhance future diagnostic accuracy. We also reviewed the records of all patients during this period who underwent coronary interventions without receiving abciximab to identify similar bleeding events occurring independent of abciximab use.

	Materials and Methods

TOP Abstract Introduction Materials and Methods Results Discussion References

 
The records of the cardiac catheterization laboratory at Mayo Clinic, Rochester were searched electronically to identify all patients who received abciximab during the study period. We identified 2,553 such patients whose records were then further examined for a diagnosis of either alveolar hemorrhage or occurrence of hemoptysis, and by cross-checking these with records of bronchoscopic procedures during this period. This was supplemented by an informal survey of staff and Fellows in the Division of Pulmonary and Critical Care Medicine for any patients they could recall with possible alveolar bleeding in the setting of a nonsurgical cardiac procedure. The records of 5,412 patients who underwent coronary procedures between January 1995 and March 2000 but did not receive abciximab were also examined for similar bleeding events.

Seven patients were identified with a diagnosis of pulmonary hemorrhage associated with abciximab use. Their records were reviewed for demographic and clinical information, including the timing and dose of abciximab, time to onset of the bleeding, symptoms, chest radiograph findings and pertinent laboratory data, details of confirmatory testing, treatment, and the ultimate outcome. The use of additional antiplatelet or anticoagulant medication was identified, as well as evidence of bleeding from other sites.

	Results

TOP Abstract Introduction Materials and Methods Results Discussion References

 
Seven patients (six men; mean age, 75 years; range, 67 to 83 years) of the 2,553 patients (0.27%) who received abciximab were identified with proven or highly probable alveolar hemorrhage. Table 1 summarizes their demographic and clinical data. No episodes of pulmonary hemorrhage were identified in the 5,412 patients who had not received abciximab, a clinically and statistically significant difference (², 11.89; Fisher’s Exact Test, p = 0.0003).

The onset of the first abnormality—hemoptysis, abnormal chest radiographic finding, or hypoxemia—ranged from 2 h to 2.6 days from the first administration of abciximab. In four of the seven patients, the presenting feature was hemoptysis; two patients presented with alveolar infiltrates, hypoxemia, and a significant (2.4 g/dL and 3.1 g/dL) decrease in hemoglobin followed by hemoptysis; and the seventh patient developed acute respiratory failure and cardiorespiratory arrest. In this patient, there was blood in the endotracheal tube and autopsy confirmed alveolar bleeding. The diagnosis was confirmed in two of the remaining six patients at bronchoscopy, with diffuse bleeding in one patient and persistent bleeding from the right upper lobe in the other patient. The first patient required ventilatory support followed by the development of acute renal failure requiring dialysis. She ultimately died 14 days after receiving abciximab when she elected to be extubated. Four diagnoses were based on major hemoptysis accompanied by a significant (> 2 g/dL) decrease in hemoglobin concentration, abnormal chest radiographic findings, and hypoxemia. One of these patients died 5 months later. An autopsy done elsewhere was reported to show bronchopneumonia but without mention of any signs of hemorrhage.

All patients showed new infiltrates on chest radiograph. These were diffusely distributed in all but one patient, who had only a right upper lobe abnormality (Fig 1 , 2). All had significantly abnormal PaO₂ levels at the time of diagnosis, and only one patient had evidence of bleeding elsewhere with hematuria and hematochezia. The latter was likely predisposed to previous radiation proctitis following treatment for prostatic carcinoma 4 years earlier. The patient declined sigmoidoscopy, and the bleeding stopped spontaneously only to recur 4 months later. All seven patients were ex-smokers, and four of the seven patients had a previous diagnosis of COPD.

View larger version (95K): [in this window] [in a new window] [Download PPT slide]   Figure 1.. Chest radiographs from patient 4 at hospital admission and after development of respiratory symptoms showing new bilateral infiltrates.

	Discussion

TOP Abstract Introduction Materials and Methods Results Discussion References

 
The use of abciximab during and after coronary angioplasty and elective stent placement has been associated with significantly improved patient outcomes, particularly a reduction in periprocedural myocardial infarction and less need for urgent reintervention. The most significant and frequent complication has been bleeding, most frequently at the vascular access site, but also from the GI tract and only rarely intracranially.^{2 5} The frequency and severity of these bleeding complications appear to correlate with body weight and the concomitant use of additional anticoagulant therapy, especially heparin but other antiplatelet drugs as well.^{2 5 6} Severe thrombocytopenia (< 20 x 10⁹/L) has been observed but has usually been transient.⁷

Alveolar hemorrhage occurred infrequently during the study period (incidence, 0.27%) with seven documented episodes among 2,553 patients. The number of patients in whom intrapulmonary bleeding might have been mild and unrecognized, or incorrectly diagnosed, is unknown. The bleeding in the seven identified patients was dramatic and likely to have been associated with the use of abciximab. The temporal association and the absence of similar episodes in patients not receiving abciximab suggest that the bleeding was likely related to the use of abciximab. Significant pulmonary hemorrhage in patients undergoing coronary procedures before abciximab became available was reported by Brown et al¹⁰ in patients seen up to 1994; 4 of 88 patients were identified with pulmonary hemorrhage following intracoronary stent placement, and 1 of these patients died. Anticoagulation measures in these patients included warfarin, heparin, aspirin, dipyridamole, and dextran infusions with activated clotting time targets of > 300 s during the procedure. Three patients, including the one who died, had activated partial thromboplastin times > 180 s at the time of bleeding. We did not identify any similar events in 5,412 patients who did not receive abciximab, and it is likely that this reflects changes in practice that have led to less intensive anticoagulation. It would therefore appear that aggressive anticoagulation can be rarely associated with pulmonary hemorrhage; but alternatively, very potent antiplatelet therapy with abciximab combined with aspirin, ticlopidine or clopidogrel, and heparin, a combination in almost routine practice currently, can also be associated with this serious complication.

In the seven patients described, there were major clinical and radiologic manifestations necessitating significant therapeutic interventions, but the small number of events does not lend itself to the identification of specific risk factors. The fact that these were mainly older patients (all men except one) with a background of cigarette smoking and at least some COPD does not necessarily define a subpopulation that may be at particular risk for this complication. However, it is reasonable to expect that the gas-exchange consequences of alveolar bleeding would be of greater severity in the setting of underlying additional lung disease.

The potential causes of hemoptysis, new radiographic infiltrates, and hypoxemia in this group of patients with severe, often unstable, coronary artery disease are numerous and include infection, heart failure, aspiration, and pulmonary thromboembolism. However, the close temporal relationship between abciximab administration and the onset of pulmonary abnormalities argues compellingly in favor of bleeding. Alveolar hemorrhage with the use of abciximab has been reported infrequently^{8 9} and may well be an underrecognized complication. The frequency of severe hemorrhage is clearly low, but the true extent of the complication remains unknown.

Transient hypoxemia, new radiologic infiltrates, and mild hemoptysis may be misattributed to pulmonary edema or pneumonia and all but the most obvious bleeding misdiagnosed. This would potentially expose patients to inappropriate treatment for heart failure or the unnecessary use of antibiotics for presumed pneumonia. In addition, the recognition of the complication could lead to an early discontinuation of the postprocedure abciximab infusion as well as prevent the inappropriate use of heparin and additional antiplatelet drugs. One of the patients in our group was initially suspected to have a pulmonary embolism, a not-uncommon scenario in the hospitalized patient with new respiratory symptoms, but with the potential for completely inappropriate anticoagulant use. A second patient was believed to have pulmonary edema until blood was seen in the endotracheal tube placed for acute respiratory failure requiring ventilatory support.

We identified seven proven or highly probable episodes of significant alveolar bleeding occurring within 3 days of the use of abciximab that resulted in one immediate death and one death after 2 weeks, during which acute renal and respiratory failure developed. All patients required blood product transfusions and developed varying degrees of respiratory failure. This report should draw renewed attention to this potentially underrecognized complication and alert those using this drug to consider the possibility of pulmonary/alveolar bleeding as the explanation for new respiratory symptoms or radiographic abnormalities. In patients with all but the most trivial changes, bronchoscopy may be diagnostic and may even have therapeutic value, using either balloon tamponade of the affected area, if localized, or through the use of locally applied hemostatic substances, as was done in one of the patients described herein. Diagnostic flexible bronchoscopy should be considered early in all patients receiving abciximab who develop new respiratory symptoms or chest radiographic abnormalities, because treatment is likely to be significantly modified if bleeding is identified.

View larger version (103K): [in this window] [in a new window] [Download PPT slide]   Figure 2.. Patient 5 developed a dense right upper lobe consolidation and faint left upper lobe infiltrates 2 h after receiving abciximab. The hospital admission radiograph is shown on the left.

	References

TOP Abstract Introduction Materials and Methods Results Discussion References

 

1. . The EPIC Investigators. (1994) Use of monoclonal antibodies directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330,956-961[Abstract/Free Full Text]
2. . The EPILOG Investigators. (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336,1689-1696[Abstract/Free Full Text]
3. . The CAPTURE Investigators. (1997) Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349,1429-1435[CrossRef][ISI][Medline]
4. . The EPISTENT Investigators. (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352,87-92[ISI][Medline]
5. Sundlof, DW, Rerkpattanapitat, P, Wongpraparut, N, et al (1999) Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty. Am J Cardiol 83,1569-1571[CrossRef][ISI][Medline]
6. Lincoff, AM, Tcheng, JE, Califf, RM, et al (1997) PROLOG Investigators. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol 79,286-291[CrossRef][ISI][Medline]
7. Berkowitz, SD, Sane, DC, Sigmon, KN, et al (1998) Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization: evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Card 32,311-319[Abstract/Free Full Text]
8. Khanlou, H, Eiger, G, Yazdanfar, S (1998) Abciximab and alveolar hemorrhage. N Engl J Med 339,1861-1863[Free Full Text]
9. Sitges, M, Villa, FP (1997) Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor. Int J Cardiol 62,269-271[CrossRef][ISI][Medline]
10. Brown, DL, MacIsaac, AI, Topol, EJ (1994) Pulmonary hemorrhage after intracoronary stent placement. J Am Coll Cardiol 24,91-94[Abstract]

This article has been cited by other articles:

				A. Sachdeva and G. M. Matuschak Diffuse Alveolar Hemorrhage Following Alemtuzumab Chest, June 1, 2008; 133(6): 1476 - 1478. [Abstract] [Full Text] [PDF]

				S. Amanullah, B. Mina, and M. Rogers Iced Saline Bronchoalveolar Lavage -A Potential Therapeutic Option For Pulmonary Hemorrhage After Percutaneous Coronary Intervention (PCI) Chest Meeting Abstracts, October 1, 2004; 126(4): 926S - 926S. [Abstract] [PDF]

				J L Lordan, A Gascoigne, and P A Corris The pulmonary physician in critical care * Illustrative case 7: Assessment and management of massive haemoptysis Thorax, September 1, 2003; 58(9): 814 - 819. [Full Text] [PDF]

				D L Brown Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment Heart, May 1, 2003; 89(5): 535 - 537. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (18) Citing Articles via Google Scholar Google Scholar Articles by Kalra, S. Articles by Rihal, C. S. Search for Related Content PubMed PubMed Citation Articles by Kalra, S. Articles by Rihal, C. S.